Integra LifeSciences Holdings (IART)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	1,486,381	1,488,778	1,493,656	1,509,844	1,505,291	1,519,581	1,519,648	1,510,233	1,535,982	1,529,270	1,504,267	1,371,086	1,317,264	1,323,744	1,339,441	1,466,719	1,476,695	1,464,883	1,451,126	1,428,751
Receivables	US$ in thousands	259,327	256,270	258,663	253,995	263,465	248,268	237,361	234,010	231,831	222,232	229,823	223,542	225,532	218,184	179,143	245,546	275,296	281,119	296,507	279,072
Receivables turnover		5.73	5.81	5.77	5.94	5.71	6.12	6.40	6.45	6.63	6.88	6.55	6.13	5.84	6.07	7.48	5.97	5.36	5.21	4.89	5.12

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $1,486,381K ÷ $259,327K
= 5.73

The receivables turnover for Integra Lifesciences Holdings Corp has shown some fluctuations over the past eight quarters. The turnover ratio measures how efficiently the company is able to collect payment from its customers.

In Q1 2022, the receivables turnover was at its highest at 6.66, indicating that the company collected its accounts receivable nearly 6.66 times during the period. This high turnover rate suggests that the company was efficient in collecting payments from its customers.

Subsequently, in Q2 and Q3 2022, the turnover ratio slightly decreased to 6.60 and 6.30, respectively, but still remained at relatively high levels. This suggests that Integra Lifesciences Holdings Corp continued to effectively manage its accounts receivable during that period.

In Q4 2022, there was a slight drop in the receivables turnover to 5.91, which may indicate a slower collection of payments compared to the previous quarters. However, the ratio rebounded in Q1 2023 to 6.15, reflecting an improvement in the company's ability to collect receivables efficiently.

The turnover ratio then fluctuated around the 6.00 mark in Q2 and Q3 2023, with values of 5.97 and 6.02 respectively, indicating that the company's collections remained relatively stable during those quarters.

In Q4 2023, the receivables turnover decreased to 5.94, which suggests a slight decline in the efficiency of receivables collections compared to the previous quarter.

Overall, the trend in Integra Lifesciences Holdings Corp's receivables turnover indicates that the company has generally been effective in managing its accounts receivable and collecting payments from customers, although there have been some fluctuations in efficiency over the past eight quarters.